Isis, GSK amend existing ISIS-TTR Rx drug development plan
ISIS-TTR Rx is an antisense drug being developed by GSK to treat TTR amyloidosis, a genetic disease characterized by progressive dysfunction of peripheral nerves and/or heart tissue. The
AstraZeneca and Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ) have signed an exclusive licence agreement for TQC3721.